Literature DB >> 30322679

Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.

Mathilde Berger1, Anne-Lise Legeay1, Sabrine Souci2, Nathalie Streichenberger3, Luc Thomas1, Stéphane Dalle4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30322679     DOI： 10.1016/j.ejca.2018.08.021

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  4 in total

1.  Dermatomyositis, pembrolizumab, and squamous cell carcinoma of the lung.

Authors:  Claire J Wiggins; Susan Y Chon
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-08-27

Review 2.  Environmental triggers of dermatomyositis: a narrative review.

Authors:  Christina E Bax; Spandana Maddukuri; Adarsh Ravishankar; Lisa Pappas-Taffer; Victoria P Werth
Journal:  Ann Transl Med       Date:  2021-03

3.  Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.

Authors:  Naoki Hamada; Ayaka Maeda; Kaoru Takase-Minegishi; Yohei Kirino; Yumiko Sugiyama; Ho Namkoong; Nobuyuki Horita; Ryusuke Yoshimi; Hideaki Nakajima
Journal:  Front Immunol       Date:  2021-12-06       Impact factor: 7.561

4.  Drug eruptions with novel targeted therapies - immune checkpoint and EGFR inhibitors.

Authors:  Isabella Pospischil; Wolfram Hoetzenecker
Journal:  J Dtsch Dermatol Ges       Date:  2021-11       Impact factor: 5.231
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.